- Home
- QURE vs AB Comparison
QURE vs AB Comparison
Compare QURE & AB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QURE | AB |
|---|---|---|
| Founded | 1998 | 1987 |
| Country | Netherlands | United States |
| Employees | 248 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.4B |
| IPO Year | 2013 | 1994 |
Fundamental Metrics
Financial Performance| Metric | QURE | AB |
|---|---|---|
| Price | $22.67 | $35.14 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 7 |
| Target Price | ★ $66.91 | $39.57 |
| AVG Volume (30 Days) | ★ 2.2M | 309.3K |
| Earning Date | 11-09-2026 | 10-27-2026 |
| Dividend Yield | N/A | ★ 9.65% |
| EPS Growth | ★ 29.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,107,000.00 | N/A |
| Revenue This Year | $56.20 | N/A |
| Revenue Next Year | $357.08 | $8.01 |
| P/E Ratio | ★ N/A | $13.85 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.73 | $34.58 |
| 52 Week High | $71.50 | $44.11 |
Technical Indicators
Market Signals| Indicator | QURE | AB |
|---|---|---|
| Relative Strength Index (RSI) | 16.51 | 39.47 |
| Support Level | $21.91 | N/A |
| Resistance Level | $27.66 | $37.70 |
| Average True Range (ATR) | 2.17 | 0.58 |
| MACD | -2.39 | -0.09 |
| Stochastic Oscillator | 5.34 | 28.02 |
Price Performance
Historical ComparisonAbout QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
About AB AllianceBernstein Holding L.P.
AllianceBernstein provides investment management services to institutional (42% of assets under management), retail (40%), and private (18%) clients through products that include mutual funds, hedge funds, and separately managed accounts. At the end of July 2026, the company had $909.0 billion in managed assets, composed primarily of fixed-income (35% of AUM) and equity (40%) strategies, with other investments (including asset allocation services and certain other alternative investments) accounting for the remainder.